News
AbbVie breaks new ground for IL-23 drug Skyrizi in IBD
AbbVie’s Skyrizi has been approved by the FDA as a treatment for ulcerative colitis, making it the first IL-23 inhibitor indicated for both major types of inflammatory bowel disease (IBD) –
